当前位置: 首页 >> 检索结果
485. Identifying and Targeting TNF Signaling in Idiopathic Multicentric Castleman's Disease.
作者: Melanie D Mumau.;Michael V Gonzalez.;Chunyu Ma.;Abiola H Irvine.;Mateo Sarmiento Bustamante.;Saishravan Shyamsundar.;Luke Y C Chen.;David Koslicki.;David C Fajgenbaum.
来源: N Engl J Med. 2025年392卷6期616-618页 489. CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53.
作者: Karlo Perica.;Nayan Jain.;Michael Scordo.;Ruchi Patel.;Ozgur Can Eren.;Utsav Patel.;Gunes Gundem.;Dylan Domenico.;Sneha Mitra.;Nicholas D Socci.;John K Everett.;Aoife M Roche.;Angelina Petrichenko.;Gunjan L Shah.;Maria E Arcila.;Laetitia Borsu.;Jae H Park.;Steven M Horwitz.;Sergio A Giralt.;Ahmet Dogan.;Christina Leslie.;Elli Papaemmanuil.;Frederic D Bushman.;Saad Z Usmani.;Michel Sadelain.;Sham Mailankody.
来源: N Engl J Med. 2025年392卷6期577-583页
Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case of a T-cell lymphoma harboring a lentiviral integration in a known tumor suppressor, TP53, which developed in a patient with multiple myeloma after B-cell maturation antigen (BCMA) CAR T-cell therapy.
490. Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer.
作者: Alison M Schram.;Koichi Goto.;Dong-Wan Kim.;Teresa Macarulla.;Antoine Hollebecque.;Eileen M O'Reilly.;Sai-Hong Ignatius Ou.;Jordi Rodon.;Sun Young Rha.;Kazumi Nishino.;Michaël Duruisseaux.;Joon Oh Park.;Cindy Neuzillet.;Stephen V Liu.;Benjamin A Weinberg.;James M Cleary.;Emiliano Calvo.;Kumiko Umemoto.;Misako Nagasaka.;Christoph Springfeld.;Tanios Bekaii-Saab.;Grainne M O'Kane.;Frans Opdam.;Kim A Reiss.;Andrew K Joe.;Ernesto Wasserman.;Viktoriya Stalbovskaya.;Jim Ford.;Shola Adeyemi.;Lokesh Jain.;Shekeab Jauhari.;Alexander Drilon.; .
来源: N Engl J Med. 2025年392卷6期566-576页
Neuregulin 1 (NRG1) fusions are recurrent oncogenic drivers found in multiple solid tumors. NRG1 binds to human epidermal growth factor receptor 3 (HER3), leading to heterodimerization with HER2 and activation of downstream growth and proliferation pathways. The efficacy and safety of zenocutuzumab, a bispecific antibody against HER2 and HER3, in patients with NRG1 fusion-positive solid tumors are unclear.
491. Endovascular Treatment for Stroke Due to Occlusion of Medium or Distal Vessels.
作者: Marios Psychogios.;Alex Brehm.;Marc Ribo.;Federica Rizzo.;Daniel Strbian.;Silja Räty.;Juan F Arenillas.;Mario Martínez-Galdámez.;Steven D Hajdu.;Patrik Michel.;Jan Gralla.;Eike I Piechowiak.;Daniel P O Kaiser.;Volker Puetz.;Frans Van den Bergh.;Sylvie De Raedt.;Flavio Bellante.;Anne Dusart.;Victoria Hellstern.;Ali Khanafer.;Guillermo Parrilla.;Ana Morales.;Jan S Kirschke.;Silke Wunderlich.;Jens Fiehler.;Götz Thomalla.;Robin Lemmens.;Jo P Peluso.;Manuel Bolognese.;Alexander von Hessling.;Adriaan van Es.;Nyika D Kruyt.;Jonathan M Coutinho.;Carlos Castaño.;Jens Minnerup.;Wim van Zwam.;Elisabeth Dhondt.;Christian H Nolte.;Paolo Machi.;Christian Loehr.;Heinrich P Mattle.;Jan-Hendrik Buhk.;Johannes Kaesmacher.;Tomas Dobrocky.;Panagiotis Papanagiotou.;Angelika Alonso.;Markus Holtmannspoetter.;Andrea Zini.;Leonardo Renieri.;Fee Keil.;Ido van den Wijngaard.;Georg Kägi.;Mikel Terceño.;Martin Wiesmann.;Sergio Amaro.;Nikki Rommers.;Luzia Balmer.;Isabel Fragata.;Mira Katan.;Ronen R Leker.;Jeffrey L Saver.;Julie Staals.;Urs Fischer.; .
来源: N Engl J Med. 2025年392卷14期1374-1384页
Endovascular treatment (EVT) of stroke with large-vessel occlusion is known to be safe and effective. The effect of EVT for occlusion of medium or distal vessels is unclear.
497. Evolving Epidemiology of Mpox in Africa in 2024.
作者: Nicaise Ndembi.;Morenike O Folayan.;Allan Komakech.;Kyeng Mercy.;Sofonias Tessema.;Placide Mbala-Kingebeni.;Christian Ngandu.;Ngashi Ngongo.;Jean Kaseya.;Salim S Abdool Karim.
来源: N Engl J Med. 2025年392卷7期666-676页
For decades after the identification of mpox in humans in the Democratic Republic of Congo (DRC) in 1970, the disease was largely confined to the rural areas of Central and West Africa and thus did not garner broad attention. On August 13, 2024, mpox was declared a Public Health Emergency of Continental Security (PHECS) by the Africa Centers for Disease Control and Prevention (Africa CDC), a notice that was followed the next day by a declaration of a Public Health Emergency of International Concern (PHEIC) by the World Health Organization.
|